Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 17, 2008 - Issue 5
Submit an article Journal homepage
130
Views
22
CrossRef citations to date
0
Altmetric
Drug Evaluation

Vernakalant – a promising therapy for conversion of recent-onset atrial fibrillation

Gerald V Naccarelli Penn State University College of Medicine, Division of Cardiology, 500 University Dr Room H 1.511, Hershey, PA 17033, USA +1 717 531 3907; +1 717 531 4077; [email protected]
, MD,
Deborah L Wolbrette Penn State University College of Medicine, Division of Cardiology, 500 University Dr Room H 1.511, Hershey, PA 17033, USA +1 717 531 3907; +1 717 531 4077; [email protected]
, MD,
Soraya Samii Penn State University College of Medicine, Division of Cardiology, 500 University Dr Room H 1.511, Hershey, PA 17033, USA +1 717 531 3907; +1 717 531 4077; [email protected]
, MD PhD,
Javier E Banchs Penn State University College of Medicine, Division of Cardiology, 500 University Dr Room H 1.511, Hershey, PA 17033, USA +1 717 531 3907; +1 717 531 4077; [email protected]
, MD,
Erica Penny-Peterson Penn State University College of Medicine, Division of Cardiology, 500 University Dr Room H 1.511, Hershey, PA 17033, USA +1 717 531 3907; +1 717 531 4077; [email protected]
, MD,
Robert Stevenson Penn State University College of Medicine, Division of Cardiology, 500 University Dr Room H 1.511, Hershey, PA 17033, USA +1 717 531 3907; +1 717 531 4077; [email protected]
, MD &
Mario D Gonzalez Penn State University College of Medicine, Division of Cardiology, 500 University Dr Room H 1.511, Hershey, PA 17033, USA +1 717 531 3907; +1 717 531 4077; [email protected]
, MD show all
Pages 805-810 | Published online: 30 Apr 2008

Citations (22)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Alessandro Capucci, Laura Cipolletta, Federico Guerra & Irene Giannini. (2018) Emerging pharmacotherapies for the treatment of atrial fibrillation. Expert Opinion on Emerging Drugs 23:1, pages 25-36.
Read now
Federico Guerra, Maria Vittoria Matassini, Lorena Scappini, Alessia Urbinati & Alessandro Capucci. (2014) Intravenous vernakalant for the rapid conversion of recent onset atrial fibrillation: systematic review and meta-analysis. Expert Review of Cardiovascular Therapy 12:9, pages 1067-1075.
Read now
Pasquale Santangeli, Luigi Di Biase, Gemma Pelargonio, J. David Burkhardt & Andrea Natale. (2011) The pharmaceutical pipeline for atrial fibrillation. Annals of Medicine 43:1, pages 13-32.
Read now
Juan Tamargo, Ricardo Caballero, Ricardo Gómez & Eva Delpón. (2009) IKur/Kv1.5 channel blockers for the treatment of atrial fibrillation. Expert Opinion on Investigational Drugs 18:4, pages 399-416.
Read now

Articles from other publishers (18)

Maria Vittoria Matassini, Federico Guerra, Lorena Scappini, Alessia Urbinati & Alessandro Capucci. (2015) New anthyarrhythmic drugs for atrial fibrillation. Future Cardiology 11:6, pages 705-717.
Crossref
Enrico Vizzardi, Francesca Salghetti, Ivano Bonadei, Sandro Gelsomino, Roberto Lorusso, Antonio D'Aloia & Antonio Curnis. (2013) A New Antiarrhythmic Drug in the Treatment of Recent-Onset Atrial Fibrillation: Vernakalant. Cardiovascular Therapeutics 31:5, pages e55-e62.
Crossref
Francesco Buccelletti, Paolo Iacomini, Gianfranco Botta, Davide Marsiliani, Annarita Carroccia, Nicolò Gentiloni Silveri & Francesco Franceschi. (2013) Efficacy and Safety of Vernakalant in Recent‐Onset Atrial Fibrillation After the European Medicines Agency Approval: Systematic Review and Meta‐Analysis. The Journal of Clinical Pharmacology 52:12, pages 1872-1878.
Crossref
Amir Y. Shaikh, Abhishek Maan, E. Kevin Heist, Dennis A. Tighe, Gerard P. Aurigemma & David D. McManus. (2012) Management Strategies in Atrial Fibrillation in Patients With Heart Failure. Cardiology in Review 20:6, pages 288-296.
Crossref
Gerald V. Naccarelli. 2012. Electrophysiological Disorders of the Heart. Electrophysiological Disorders of the Heart 1159 1166 .
Dobromir Dobrev & Bramah N. Singh. 2012. Electrophysiological Disorders of the Heart. Electrophysiological Disorders of the Heart 1133 1157 .
Sean T. Duggan & Lesley J. Scott. (2011) Spotlight on Intravenous Vernakalant in Recent-Onset Atrial Fibrillation†. Drugs & Aging 28:6, pages 501-504.
Crossref
Alessandro Marinelli, Iacopo Ciccarelli & Alessandro Capucci. (2011) Vernakalant hydrochloride in the treatment of atrial fibrillation: a review of the latest clinical evidence. Clinical Investigation 1:4, pages 579-588.
Crossref
Soraya M. Samii & Gerald V. Naccarelli. (2011) AVRO—were the results a surprise?. Nature Reviews Cardiology 8:4, pages 188-190.
Crossref
Sean T. Duggan & Lesley J. Scott. (2011) Intravenous Vernakalant. Drugs 71:2, pages 237-252.
Crossref
David Tian & William H. Frishman. (2011) Vernakalant. Cardiology in Review 19:1, pages 41-44.
Crossref
Dobromir Dobrev & Stanley Nattel. (2010) New antiarrhythmic drugs for treatment of atrial fibrillation. The Lancet 375:9721, pages 1212-1223.
Crossref
Donald M. Yealy & Theodore R. Delbridge. 2010. Rosen's Emergency Medicine – Concepts and Clinical Practice. Rosen's Emergency Medicine – Concepts and Clinical Practice 984 1024 .
Joachim R. Ehrlich & Stanley Nattel. (2009) Novel Approaches for Pharmacological Management of Atrial Fibrillation. Drugs 69:7, pages 757-774.
Crossref
Joachim R Ehrlich & Stanley Nattel. (2009) Atrial-selective pharmacological therapy for atrial fibrillation: hype or hope?. Current Opinion in Cardiology 24:1, pages 50-55.
Crossref
Jerzy Karczewski, Laszlo Kiss, Stefanie A. Kane, Kenneth S. Koblan, Robert J. Lynch & Robert H. Spencer. (2009) High-throughput analysis of drug binding interactions for the human cardiac channel, Kv1.5. Biochemical Pharmacology 77:2, pages 177-185.
Crossref
R. Gopinathannair & B. Olshansky. (2008) Ibutilide revisited: stronger and safer than ever. Europace 11:1, pages 9-10.
Crossref
Peter WeekeCharlotte AnderssonBente BrendorpChristian Torp-Pedersen. (2008) Vernakalant (RSD1235) in the management of atrial fibrillation: a review of pharmacological properties, clinical efficacy and safety. Future Cardiology 4:6, pages 559-567.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.